Cetrotide (INN cetrorelix) – is the first and only gonadotropin releasing hormone antagonist that offers dosing simplicity and flexibility. It is injected subcutaneously (just under the skin). Cetrotide is available in a 3mg single-dose regimen and a 0.25mg daily dose given on stimulation day five or seven, depending on the strength.
Cetrotide is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide should be prescribed by physicians who are experienced in fertility treatment. Cetrotide is contraindicated in women who exhibit hypersensitivity to cetrorelix acetate, mannitol or exogenous peptide hormones, who exhibit prior hypersensitivity to GnRH or any other GnRH analogs, or who are pregnant, or breast-feeding or severe renal impairment. Ovarian hyperstimulation syndrome (OHSS), with or without vascular and pulmonary complications, can occur with the use of fertility drugs. Mild and short lasting injection reactions like reddening, itching and swelling at the injection sites may occur. Nausea and headache have also been reported.
